Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study
Executive Summary
The biotech argues that success in reducing fibrosis is more important than the failed primary endpoint measuring NAFLD activity score improvement – and also meets FDA's expectations – but the firm is taking a beating nonetheless.
You may also be interested in...
Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived
Genfit believes elafibranor’s clean tolerability and safety profile may help narrow the gap between it and Intercept’s OCA, with safety questions delaying OCA’s entry to market. Part two of Scrip’s interview with Genfit’s CEO and COO.
Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit
A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.
Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?
Novartis is teaming up with Allergan in a bid to get a treatment on the market for the fatty liver disease NASH, which currently has no approved treatments. The decision by Novartis to test its lead FXR agonist with Allergan's cenicriviroc (CVC) is interesting because Allergan's product reported mixed Phase II data.